Not a good buy right now for an impatient investor: the technical setup is still bearish (negative/expanding MACD) and there are no near-term catalysts.
Price is sitting just above key support (S1 ~13.49). That can produce a short bounce, but it’s not strong enough to justify a fresh buy without a clear trigger.
No recent news flow, no notable hedge fund/insider trend, and no congress trading data—so there’s limited confirmation from external sentiment.
Technical Analysis
Trend/Momentum: Bearish momentum is building (MACD histogram -0.107 below zero and negatively expanding).
RSI(6): 32.806 (weak/near oversold). This can support a brief rebound, but by itself it’s not a buy signal while MACD worsens.
Moving averages: Converging MAs suggests consolidation rather than a clean trend reversal.
Key levels: Support S1 13.494 (very near current 13.6); next support S2 12.757. Resistance/pivot 14.688, then R1 15.882.
Tactical read: If support breaks, downside can accelerate toward ~12.76. To turn constructive, it needs to reclaim and hold above ~14.69 (pivot).
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put/Call OI = 0.66 (more calls than puts outstanding) → moderately bullish longer-horizon positioning.
Flow (Today’s Volume): Put/Call volume = 1.37 with puts (52) > calls (38) → bearish/hedging tone today.
Volatility: 30D IV 114.15 vs HV 56.03 → options are pricing large moves; however IV is below recent 5D/10D averages, implying IV has been coming down.
Activity: Today’s option volume (90) is far below the 5D/10D average volume (913/536), so the day’s put-heavy read is not very “high-conviction.”
Technical Summary
Sell
11
Buy
2
Positive Catalysts
suggests more bullish positioning overall.
Neutral/Negative Catalysts
Momentum is still deteriorating (MACD negative and expanding), which often precedes further downside.
No news in the last week → no obvious event-driven catalyst to force a re-rating upward.
Options imply very large move risk (IV far above HV), and today’s flow is put-leaning (volume put/call 1.37).
Trading trends: hedge funds and insiders are neutral—no strong “smart money” tailwind visible from the provided data.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 351,000 (flat YoY per provided data; very small base).
Profitability: Net income 8,204,000, down -90.76% YoY.
EPS: 0.94, down -91.92% YoY.
Overall: The quarter shows sharply worse earnings power vs last year (even if revenue is steady), which weakens the fundamental near-term buy case.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating / price target change data was provided, so a recent trend in upgrades/downgrades cannot be verified here.
Wall Street pros/cons view (based strictly on provided info):
Pros: Potential technical bounce near support; options open-interest skew is somewhat call-heavy.
Cons: Deteriorating momentum, weak YoY earnings trend in 2025/Q3, and no visible catalysts or notable institutional/insider/congress activity in the provided dataset.
Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 22 USD with a low forecast of 22 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 22 USD with a low forecast of 22 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.400
Low
22
Averages
22
High
22
Current: 13.400
Low
22
Averages
22
High
22
Canaccord
Buy
maintain
$14 -> $22
AI Analysis
2025-09-24
Reason
Canaccord
Price Target
$14 -> $22
AI Analysis
2025-09-24
maintain
Buy
Reason
Canaccord raised the firm's price target on Seres Therapeutics to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres' proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions while also noting Seres is reducing staff by 25%, including August 2025 reductions, which should provide sufficient cash to fund operations into 2Q26.
Chardan
Buy -> Neutral
downgrade
$6
2025-05-08
Reason
Chardan
Price Target
$6
2025-05-08
downgrade
Buy -> Neutral
Reason
Chardan downgraded Seres Therapeutics to Neutral from Buy with a $6 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MCRB
